An orexin pill sharply improved wakefulness in narcolepsy type 1
In the phase 2 Vibrance-1 trial, alixorexton lifted mean sleep latency from about 2 minutes on placebo to 24 or more on the drug. The six-week study was funded by the manufacturer.
For how we live.
In the phase 2 Vibrance-1 trial, alixorexton lifted mean sleep latency from about 2 minutes on placebo to 24 or more on the drug. The six-week study was funded by the manufacturer.
For a few seconds to a couple of minutes you are awake but frozen, sometimes with a sense of a presence in the room. It is REM sleep intruding into wakefulness — common, frightening and, on its own, harmless.
The comparison group matters: against veterans with unspecified narcolepsy diagnoses, the mortality gap widened to 140% higher odds. The study can't yet say what's driving the excess deaths.